Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Merck
Cantor Fitzgerald
McKinsey
Julphar
Citi
UBS
Covington
Farmers Insurance

Generated: February 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,923,564

« Back to Dashboard

Summary for Patent: 7,923,564
Title:Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Abstract: Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
Inventor(s): Thygesen; Mikkel Boas (Copenhagen East, DK), Schlienger; Nathalie (Frederiksberg, DK), Tolf; Bo-Ragnar (Malmo, SE), Andersson; Carl-Magnus A. (Hjarup, SE), Blatter; Fritz (Reinach, CH), Berghausen; Jorg (Lorrach, DE)
Assignee: ACADIA Pharmaceuticals, Inc. (San Diego, CA)
Application Number:12/795,547
Patent Claims: 1. Crystalline form C of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide tartrate of formula IV, ##STR00032## which shows an endothermic signal at 177.degree. C. as measured by differential scanning calorimetry.

2. The crystalline form of claim 1, wherein the endothermic signal at 177.degree. C. has an enthalpy of fusion of about 129 J/g.

3. The crystalline form of claim 1, wherein the endothermic signal at 177.degree. C. is a melting temperature.

4. The crystalline form of claim 1, which results in a weight loss of about 0.9% below 150.degree. C. as measured by thermogravimetric analysis.

5. The crystalline form of claim 1 that has less than 1000 ppm of residual solvent.

6. The crystalline form of claim 1 that has less than 200 ppm of residual solvent.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Farmers Insurance
Fuji
Boehringer Ingelheim
Healthtrust
Cipla
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot